Elan invests $20m in Proteostasis and agrees a further $30m in funding
This article was originally published in Scrip
Executive Summary
Elan, which just raised $500 million by divesting its formulation and manufacturing business Elan Drug Technologies (EDT), is investing $20 million in Proteostasis Therapeutics of the US as part of a drug discovery partnership focused on small molecules to treat neurodegenerative disorders including Parkinson's disease and Alzheimer's disease.